NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Novavax, Inc., a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first phase 3 study to evaluate the ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F.

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Add Yahoo as a preferred source to see more of our stories on Google. The recommendation, made by the CDC's Advisory Committee on Immunization Practices, acknowledges the increased risk of severe ...

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...